Navigation Links
NeurogesX Reports First Quarter 2009 Results
Date:5/7/2009

the NDA; NeurogesX' plans, and expected timing, with regard to seeking partnerships for its product candidates; the sufficiency of cash resources to fund the NeurogesX' operations through at least December 31, 2009; the ability to secure funding through commercial partnerships; expectations regarding expenses and cash burn rate; expectations with respect to seeking funding; the potential markets for NeurogesX' product candidates; and the expected benefits of NeurogesX' product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, positive results in clinical trials, or the recommendation of the CHMP for MAA approval, may not be sufficient to obtain FDA or European regulatory approval; any regulatory approvals which are received may offer more limited indications than anticipated; unexpected expenses; inability to enter into or obtain adequate funding under commercial or other strategic partnerships; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; physician or patient reluctance to use Qutenza or NGX-1998, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of NeurogesX' product candidates and the advantages of NeurogesX' product candidates over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.


                                     NEUROGESX, INC.
                             
'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
2. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
3. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
4. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
5. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
6. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. NeurogesX Reports Third Quarter 2008 Results
8. NeurogesX to Report Third Quarter 2008 Financial Results
9. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
10. NeurogesX Responds to EMEAs Day 120 Questions
11. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 2015  UBM Medica US announces that ... community to help oncologists and other clinicians gain ... regarding the use of targeted therapies and immunotherapies, ... March is National Kidney Cancer Awareness Month ... treatment options for renal cell carcinoma (RCC) patients. ...
(Date:3/5/2015)... March 05, 2015 e2b teknologies ... Partner located in Northeast Ohio, today announced a leading ... to support its upgrade to the latest version of ... independent group practice of its kind in the region, ... volume of transactions, so efficiency and data accessibility are ...
(Date:3/4/2015)... , March 4, 2015 PDL BioPharma, Inc. (PDL) ... conversion rate for the: , 3.75% Convertible Senior ... shares of common stock per $1,000 principal amount or approximately ... conversion rate for the note is adjusted in connection with ... March 12, 2015, to all stockholders who own shares of PDL ...
(Date:3/4/2015)...  Brooklyn residents now have a new place to ... injuries. Nunzio Saulle , M.D., a board-certified physiatrist, ... NJS Physical Medicine and Rehabilitation (PM&R) practice in ... 2015. Health Plus Management, LLC is managing the day-to-day ... Flatbush Avenue. This new PM&R practice will treat patients ...
Breaking Biology Technology:OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2
... March 13 Varian Medical Systems (NYSE: VAR ... the non-destructive testing market at the upcoming ASNT Research Symposium ... Millennium Hotel in St. Louis, MO.The company will exhibit a ... , ...
... Technology (TU/e) have for the first time made ... formation. They used the world,s most advanced electron ... that are at the heart of the process. ... and shell formation. For industrial applications, they promise ...
... Call on Friday, March 13, 2009 at 8:30am ... Inc. (Nasdaq: KERX ), a biopharmaceutical ... of medically important, novel pharmaceutical products for the ... cancer (the "Company"), today announced its results for ...
Cached Biology Technology:Varian Medical Systems to Exhibit X-ray and CT Technologies for Non-Destructive Testing at the Upcoming ASNT 18th Annual Spring Conference 2First high-resolution images of bone, tooth and shell formation 2Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 5Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 6
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/48tj8z/global_biometrics ... "Global Biometrics Market Forecast and Opportunities, 2020" ... for biometric authentication systems is projected to grow ... The driving forces for this highly ... projects and constant development in technology. In 2014, ...
(Date:2/25/2015)... ROCK, Ark. , Feb. 25, 2015 /PRNewswire/ ... software and billing in the Health and Fitness ... as well as to MYiCLUBonline.  The latest upgrade ... and the inclusion of cardless check-in via Identity ... for the first time through interactive displays at ...
(Date:2/19/2015)... Feb .19, 2015 Research and Markets ... of the "Military Electro-Optical / Infrared Systems ... by Platform - Forecast to 2020" report ... electro-optical/infrared systems market is expected to reach $16.35 ... 7.71%. This report segments the military ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3
... University of Guelph researchers has proven up to 88 ... to a new U of G study. The ... Research International . It,s a crucial finding because ... poses economic, health, legal and environmental implications, says study ...
... New Rochelle, NY, September 19, 2012-- Researchers have successfully ... from mice that can be grown in large quantities ... develop into many different cell types needed throughout the ... cell biology and human development and disease is described ...
... KNOXVILLEShoppers particularly women who take the time ... don,t. These findings are from a recently released ... Tennessee professor in the Institute of Agriculture,s Department of ... the University of Santiago de Compostela in Spain, the ...
Cached Biology News:Study: DNA barcoding can ID natural health products 2
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
... recombinant human protein produced in E. coli and ... A type enzymes. The mode of inhibition ... a 1:1 ratio. The enzyme has been shown ... cell types. Addition of the ribonuclease inhibitor has ...
Biology Products: